APA (7th ed.) Citation

RH, K., J, L., I, M., JF, M., AL, K., B, R., . . . S, G. (2022). Long-term efficacy, safety, and tolerability of a subcutaneous immunoglobulin 16.5% (cutaquig®) in the treatment of patients with primary immunodeficiencies. Clinical and experimental immunology, 210(2), 91. https://doi.org/10.1093/cei/uxac092

Chicago Style (17th ed.) Citation

RH, Kobayashi, et al. "Long-term Efficacy, Safety, and Tolerability of a Subcutaneous Immunoglobulin 16.5% (cutaquig®) in the Treatment of Patients with Primary Immunodeficiencies." Clinical and Experimental Immunology 210, no. 2 (2022): 91. https://doi.org/10.1093/cei/uxac092.

MLA (9th ed.) Citation

RH, Kobayashi, et al. "Long-term Efficacy, Safety, and Tolerability of a Subcutaneous Immunoglobulin 16.5% (cutaquig®) in the Treatment of Patients with Primary Immunodeficiencies." Clinical and Experimental Immunology, vol. 210, no. 2, 2022, p. 91, https://doi.org/10.1093/cei/uxac092.